EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Swedish matched cohort on the association between maternal polyendocrine metabolic ovarian syndrome and next-generation cancer risk

Romina Fornes, Unnur Gudnadottir, Sheila Orwa, Michael Saerens, Elisabet Stener-Victorin, Nele Brusselaers

JNCI Cancer Spectrum · 2026-09-03 · 10 (5)

DOI: 10.1093/jncics/pkag104 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Polyendocrine metabolic ovarian syndrome (PMOS) is an endocrine and metabolic disorder associated with adverse perinatal and long-term health outcomes, yet its impact on cancer risk in children remains unclear. Methods We conducted a nationwide, register-based matched cohort study in Sweden, including children of primiparous women with (N = 22 955) and without PMOS (N = 103 613) born between 1973 and 2018. Children were followed from birth until cancer diagnosis, death, or December 2018. Conditional Cox proportional hazards models estimated the adjusted hazard ratio (aHR) with 95% CI, incorporating time-varying effects when the proportional hazards assumption was violated. Results During follow-up, 666 children were diagnosed with cancer. Compared with children born to women without PMOS, overall cancer risk among children of women with PMOS differed by sex and over time. Among sons, higher hazards at 1 year were observed (aHR = 4.17; 95% CI = 2.51 to 6.93), decreasing by 10 years (aHR = 1.53; 95% CI = 1.08 to 2.18). In daughters, hazard ratios did not indicate a change in overall cancer risk compared to reference. When both sexes were combined, risk of lymphatic and hematopoietic malignancies was higher (aHR = 2.43; 95% CI = 1.36 to 4.33). Competing risks of death did not materially alter the associations. Conclusions Overall cancer risk among children born to women with PMOS differed by sex and over time, with higher risks in sons during early life. These findings suggest that maternal PMOS may be associated with differential cancer susceptibility across the life course.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →